CTOs on the Move

Precigen

www.precigen.com

 
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.precigen.com
  • 20358 Seneca Meadows Parkway
    Germantown, MD USA 20876
  • Phone: 301.556.9900

Executives

Name Title Contact Details

Funding

Precigen raised $35M on 02/03/2020

Similar Companies

BioMotiv

BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.

Acris Antibodies

Acris Antibodies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Augustine Biomedical Design

Augustine Biomedical Design is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Armata Pharmaceuticals

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.

Readcoor

ReadCoor is leading the next generation of `omics` by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is accomplishing this with a fundamental new technology called FISSEQ which simultaneously enables integration of high throughput sequencing, morphometric analysis, cellular location and three dimensional spatial imaging. This uniquely powerful tool is the first and only implementation of `In-situ Sequencing` and will revolutionize the next phase in understanding the transcriptome, introducing vast new opportunities for important and meaningful clinical insight. ReadCoor will fulfill the mission with a comprehensive set of high quality services, systems and actionable information provided to research and healthcare communities worldwide. Current transcriptomic tools are cumbersome, inadequate and cannot preserve the rich panomic information contained in cellular structures. ReadCoor combines both next generation sequencing and morphometric information for the first time in a new generation sequencing platform that enables researchers to perform high throughput RNA sequencing without dissociating cells, thus preserving important cellular structures, pinpointing transcripts to individual cells in 3D, and delivering high fidelity spatial image data.